Product Data Sheet

Fenoverine-d₈

Cat. No.: HY-107349S

Molecular Formula: C₂₆H₁₇D₈N₃O₃S

Molecular Weight: 467.61

Target: Calcium Channel

Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (213.85 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg | |
|------------------------------|-------------------------------|-----------|------------|------------|--|
| | 1 mM | 2.1385 mL | 10.6927 mL | 21.3853 mL | |
| | 5 mM | 0.4277 mL | 2.1385 mL | 4.2771 mL | |
| | 10 mM | 0.2139 mL | 1.0693 mL | 2.1385 mL | |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Fenoverine-d₈ is the deuterium labeled Fenoverine[1]. Fenoverine (Spasmopriv) is an antispasmodic agent and inhibits calcium channel currents[2]. Fenoverine induces rhabdomyolysis[3].

In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs $^{[1]}$.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

 $[1]. \ Russak\ EM, et\ al.\ Impact\ of\ Deuterium\ Substitution\ on\ the\ Pharmacokinetics\ of\ Pharmaceuticals.\ Ann\ Pharmacother.\ 2019\ Feb; 53(2): 211-216.$

[2]. J Mironneau, et al. Fenoverine inhibition of calcium channel currents in single smooth muscle cells from rat portal vein and myometrium. Br J Pharmacol. 1991 Sep;104(1):65-70.

| 3]. Chung-Wen Chen, et al. Rha | abdomyolysis induced by fenc | overine: a case report and litera | ature review. Acta Neurol Taiwan. | 2005 Sep14(3):143-6. | |
|--------------------------------|-----------------------------------|--|--|----------------------|--|
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | edical applications. For resea | | |
| | Tel: 609-228-6898 Address: 1 [| Fax: 609-228-5909 Deer Park Dr, Suite Q, Monm | E-mail: tech@MedChemouth Junction, NJ 08852, USA | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

Page 2 of 2 www.MedChemExpress.com